Fisetin vs Quercetin
Two flavonoids with senolytic reputations neither has earned in humans. Fisetin's case is entirely in mice; quercetin's belongs to a drug combination, not to quercetin alone.
Short answer
Quercetin rests on firmer ground than fisetin, with human clinical data against only preclinical or minimal evidence, resting mostly on animal or lab work. Someone focused on senolytic use, blood pressure and immunity has trial data to go on with quercetin; fisetin, marketed for senolytic use and anti-aging, is still an early-research option.
Fisetin
The most potent senolytic flavonoid in mice, with lifespan data — but the one human trial to report a clinical outcome (ROPE, knee osteoarthritis) was null; other senolytic-hypothesis trials remain unpublished.
Full Fisetin evidence reviewQuercetin
Modest, real blood-pressure benefit; its senolytic fame belongs to the dasatinib+quercetin combo in tiny pilots, not quercetin alone.
Full Quercetin evidence reviewFisetin vs Quercetin: head to head
- FDA status / approved use
Fisetin
Sold as a dietary supplement, not an approved drug; senolytic use is investigationalQuercetin
Sold as a supplement; also a normal part of the diet- Marketed for
Fisetin
Senolytic, anti-agingQuercetin
Senolytic, blood pressure, immunity- Outcome areas
Fisetin
Cellular senescence; Longevity / lifespan; Joint / bone healthQuercetin
Cardiovascular; Cellular senescence; Immune function / inflammation- Evidence grade
Fisetin
Preclinical / minimalQuercetin
Clinical data- How it works
Fisetin
Senolytic: clears senescent 'zombie' cells, shown mainly in miceQuercetin
Dietary flavonoid; acts as a senolytic only combined with dasatinib- Route and dosing
Fisetin
Oral supplement, often taken in high intermittent dosesQuercetin
Supplement capsule; blood pressure effect strongest at ≥500 mg/day- Headline human result
Fisetin
No significant benefit for knee pain, function or cartilage at three months in the 2025 ROPE osteoarthritis RCTQuercetin
About 3.0 mmHg lower systolic and 2.6 mmHg lower diastolic blood pressure in a meta-analysis of 7 RCTs- Strongest evidence
Fisetin
Mouse senolytic, EBioMedicine 2018. Little or no controlled human outcome data for the marketed useFisetin evidence reviewPubMed 30279143Quercetin
BP meta-analysis, JAHA 2016Quercetin evidence reviewPubMed 27405810- Key safety signal
Fisetin
Looks safe as a food compound; long-term safety of high senolytic doses is not establishedQuercetin
Well tolerated; high doses can cause mild GI effects; drug-interaction caution applies- How it is obtained
Fisetin
Over the counter as a dietary supplementQuercetin
Over the counter as a dietary supplement
| Fisetin | Quercetin | |
|---|---|---|
| FDA status / approved use | Sold as a dietary supplement, not an approved drug; senolytic use is investigational | Sold as a supplement; also a normal part of the diet |
| Marketed for | Senolytic, anti-aging | Senolytic, blood pressure, immunity |
| Outcome areas | Cellular senescence; Longevity / lifespan; Joint / bone health | Cardiovascular; Cellular senescence; Immune function / inflammation |
| Evidence grade | Preclinical / minimal | Clinical data |
| How it works | Senolytic: clears senescent 'zombie' cells, shown mainly in mice | Dietary flavonoid; acts as a senolytic only combined with dasatinib |
| Route and dosing | Oral supplement, often taken in high intermittent doses | Supplement capsule; blood pressure effect strongest at ≥500 mg/day |
| Headline human result | No significant benefit for knee pain, function or cartilage at three months in the 2025 ROPE osteoarthritis RCT | About 3.0 mmHg lower systolic and 2.6 mmHg lower diastolic blood pressure in a meta-analysis of 7 RCTs |
| Strongest evidence | Mouse senolytic, EBioMedicine 2018. Little or no controlled human outcome data for the marketed useFisetin evidence reviewPubMed 30279143 | BP meta-analysis, JAHA 2016Quercetin evidence reviewPubMed 27405810 |
| Key safety signal | Looks safe as a food compound; long-term safety of high senolytic doses is not established | Well tolerated; high doses can cause mild GI effects; drug-interaction caution applies |
| How it is obtained | Over the counter as a dietary supplement | Over the counter as a dietary supplement |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
- Preclinical / minimal:
- Evidence is largely animal, in-vitro, or anecdotal. Little or no controlled human outcome data for the marketed use.
Our verdict
Neither is an established senolytic in people. Fisetin was the most potent senolytic of the flavonoids screened and extended both median and maximum lifespan in old mice, but there is no published human trial showing a senolytic or longevity benefit; the studies designed to test it are still ongoing, and that use is explicitly investigational. Quercetin's senolytic fame comes from the dasatinib plus quercetin combination tested in open-label pilots of 9 to 14 people, and dasatinib is a prescription chemotherapy drug; on its own, quercetin's one well-supported human benefit is a modest blood-pressure reduction of about 3.0 mmHg systolic and 2.6 mmHg diastolic, strongest at 500 mg/day or more. The two have not been compared directly.
Fisetin fits if
Someone following the senolytic hypothesis early who is honest that they are acting on animal data while the human trials run.
Quercetin fits if
Someone who wants a low-risk dietary flavonoid with one genuinely supported human benefit, taken for modest blood-pressure support rather than for clearing senescent cells.
Fisetin vs Quercetin: common questions
- Is either fisetin or quercetin FDA-approved?
- No. Fisetin is sold as a dietary supplement, not an approved drug; senolytic use is investigational. Quercetin is sold as a supplement; also a normal part of the diet.
- Which has stronger human evidence, fisetin or quercetin?
- Quercetin. It has human clinical data (key source: BP meta-analysis, JAHA 2016), while fisetin has only preclinical or minimal evidence (key source: Mouse senolytic, EBioMedicine 2018).
- What are the main safety concerns with fisetin and quercetin?
- Fisetin looks safe as a food compound; long-term safety of high senolytic doses is not established. Quercetin is well tolerated; high doses can cause mild GI effects; drug-interaction caution applies.
Key studies behind each
Fisetin
- Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. (2018). Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. PubMed 30279143
- Murray KO, Mahoney SA, Ludwig KR, et al. (2025). Intermittent Supplementation With Fisetin Improves Physical Function and Decreases Cellular Senescence in Skeletal Muscle With Aging. Aging Cell. PubMed 40437670
- Silva M, Wacker DA, Driver BE, et al. (2024). Senolytics To slOw Progression of Sepsis (STOP-Sepsis) in elderly patients: Study protocol for a multi-center, randomized, adaptive allocation clinical trial. Trials. PubMed 39434114
- Ji J, Crespi CM, Yee L, et al. (2026). A phase II randomized placebo-controlled study of fisetin to improve physical function in breast cancer survivors: the TROFFi study rationale and trial design. Ther Adv Med Oncol. PubMed 41835341
Quercetin
- Serban MC, Sahebkar A, Zanchetti A, et al. (2016). Effects of Quercetin on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. PubMed 27405810
- Justice JN, Nambiar AM, Tchkonia T, et al. (2019). Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine. PubMed 30616998
- Hickson LJ, Langhi Prata LGP, Bobart SA, et al. (2019). Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine. PubMed 31542391
- Pelletier DM, Lacerte G, Goulet ED. (2013). Effects of quercetin supplementation on endurance performance and maximal oxygen consumption: a meta-analysis. Int J Sport Nutr Exerc Metab. PubMed 22805526
The full evidence reviews
- Fisetin: a powerful senolytic in mice, unproven in humans
A dietary flavonoid that's the most potent senolytic of its class and extends lifespan in mice — but the human trials that would test the senolytic claim are still ongoing, with no published outcomes.
Updated August 2026
- Quercetin: one real benefit, and a reputation that outruns it
A flavonoid with modest, meta-analysis-backed blood-pressure benefit — but its 'senolytic' fame belongs to the dasatinib+quercetin combo, and its exercise and allergy claims are weak.
Updated August 2026